The Journal of thoracic and cardiovascular surgery
-
J. Thorac. Cardiovasc. Surg. · Nov 1984
Randomized Controlled Trial Comparative Study Clinical TrialA clinical trial of blood and crystalloid cardioplegia.
Although experimental studies suggest that blood cardioplegia provides better protection than crystalloid cardioplegia, clinical studies have been inconclusive. Ninety patients undergoing coronary bypass grafting were randomized to receive either blood (n = 43) or crystalloid cardioplegia (n = 47). The incidence of perioperative myocardial infarction was lower with blood cardioplegia (blood, n = 0; crystalloid, n = 5; p = 0.06), and the maximum MB isoenzyme of creatine kinase was significantly less with blood cardioplegia (blood, 26.3 +/- 12.6 U/L; crystalloid, 35.6 +/- 17.0 U/L, mean +/- standard deviation; p less than 0.02.) Sixty patients (blood cardioplegia, n = 28; crystalloid cardioplegia, n = 32) had more sensitive measurements to assess the metabolic response to aortic occlusion and to compare the metabolic and functional recovery from the operation. ⋯ Myocardial performance (the left ventricular stroke work index-left ventricular end-diastolic volume index relation) and systolic elastance (the systolic blood pressure-left ventricular end-systolic volume index relation) were significantly better with blood cardioplegia (p less than 0.01 by multivariate analysis); diastolic compliance (the left atrial pressure-left ventricular end-diastolic volume index relation) was similar. Blood cardioplegia reduced ischemic injury, decreased anaerobic metabolism during arrest, and permitted better functional recovery. Blood cardioplegia provides superior protection for elective coronary bypass grafting and may improve the clinical results in patients with unstable angina and in other high-risk patients.
-
J. Thorac. Cardiovasc. Surg. · Nov 1984
The St. Jude Medical bileaflet valve prosthesis. A 5 year experience.
A 5 year experience with the bileaflet St. Jude Medical valve is reported. Between March, 1978, and June, 1982, 198 patients received 233 such valves (90 mitral, 73 aortic, and 35 double mitral-aortic valve replacements). ⋯ This intermediate experience with the St. Jude Medical valve indicates that, in addition to its previously demonstrated excellent hemodynamic performance, there have been no instances of primary structural failure or hemolysis. Warfarin anticoagulation is recommended in all patients.
-
J. Thorac. Cardiovasc. Surg. · Nov 1984
Coronary artery bypass for unsuccessful percutaneous transluminal coronary angioplasty.
Of 518 consecutive patients undergoing percutaneous transluminal coronary angioplasty for 571 coronary lesions, 184 eventually underwent coronary artery bypass because of angioplasty failure. Delayed coronary bypass (1 week to 19 months) was done in 27 patients with no deaths. Immediate bypass was done in 87 patients with two deaths, both of which were caused by further dissection of the artery after angioplasty. ⋯ In the 10 patients in whom extracorporeal circulation was established within 25 minutes of myocardial insult, mortality and myocardial complications were completely avoided. The remaining patients in the urgent group were placed on cardiopulmonary bypass within 26 to 300 minutes (mean 82 minutes). Operative mortality (3.3%), completed myocardial infarction (6.0%), myocardial infarction in unstable patients (32.9%), postoperative hemorrhage (5.0%), and sternal problems (2.8%) were all significantly different from those in 3,500 consecutive coronary bypasses not following angioplasty, that were done in 1982.
-
J. Thorac. Cardiovasc. Surg. · Nov 1984
Biography Historical ArticleEvarts Graham and surgical residency education.
-
J. Thorac. Cardiovasc. Surg. · Nov 1984
Late surgical results for ischemic mitral regurgitation. Role of wall motion score and severity of regurgitation.
The indication for concomitant valve operations for ischemic mitral regurgitation is examined in 120 consecutive patients with regurgitation who had coronary bypass. Ischemic mitral regurgitation was mild in 56%, moderate in 18%, and severe in 27%. Compared with patients without mitral regurgitation who underwent coronary bypass, significantly more patients with regurgitation had cardiomegaly (31% versus 5%), left heart failure (42% versus 6%), and abnormal wall motion scores (71% versus 42%). ⋯ Mild regurgitation is best managed by coronary bypass alone. If regurgitation is moderate, it may still be possible to avoid a valve operation and have acceptable results. Severe ischemic mitral regurgitation usually necessitates coronary bypass and a mitral valve operation.